Forsyth Barr says Abano shares should outperform
Abano shares are trading at a discount to both the New Zealand market and its Australian peers.
Jenny Ruth
Mon, 27 Mar 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Forsyth Barr analyst Chelsea Leadbetter has resumed coverage of Abano Healthcare following the failure of the recent takeover attempt and says the shares should outperform.
Abano’s largest shareholder, Healthcare Partners, had wanted to take its stake from 19% to just above 50% but its $10 per
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Jenny Ruth
Mon, 27 Mar 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.